Treato Research of 134,000 Melanoma Discussions Reveals the 'Under 30s' Most Active Online

PRINCETON, New Jersey, May 13, 2015 /PRNewswire/ --

In support of Melanoma Awareness Month, Treato analyzed the voice and insights from over 134,000 consumer conversations across the Internet about Melanoma. As we head into prime suntan and sunburn season, this in-depth look offers some interesting insights on the status of skin cancer from the perspective of health consumers.

Treato's analytics discovered that 19-29-year-olds are the most active age group discussing melanoma today. This discovery coincides with the Skin Cancer Foundation information that melanoma is the most common form of cancer for young adults 25-29 years old, and the second most common form of cancer for young people 15-29 years old. Treato further discovered that posts among those in the 19-39 age groups make up nearly 60% of discussions about being newly diagnosed.

Among the 134K posts gathered and analyzed, the overall skew is slightly female at 54% to 46% male. Yet, when it comes to discussions around clinical trials for skin cancer, the reverse is true - men comprise 56% of those posts. These discussions skew to an older demographic, with 53% over the age of 40.  

Additional findings from the Treato analysis include:

• Discussions around genetic testing for skin cancer have nearly doubled since 2009. This is likely a result of the introduction of drugs such as Zelboraf, targeted specifically to a certain gene mutation coupled with melanoma; and the increased availability and reduced costs of genetic testing.
• Patient posts related to skin cancer biopsy grew five times since 2006, showing the importance of early detection and prevention.
• Melanoma Research Foundation's #GetNaked campaign ranked one of the top four topics on Twitter since it launched last year, just behind #melanoma and #skincancer.

"Our ability to look at what billions of real health consumers are discussing online provides insights that just can't be obtained any other way," says Ido Hadari, CEO of Treato.com. "Engaging consumers, particularly the younger audiences, as this research demonstrates, is key to successfully increasing awareness of and making an impact on the growth of skin cancer. By gaining a deep understanding of what individuals think and how they behave, and then addressing their concerns in a place and manner that best suits them, the healthcare industry can effectively engage these individuals in an effort to create better health outcomes."

Find more information and statistics on Treato's Melanoma Infographic.

About Treato 

Treato™, the leading source of real health insights from millions of real health consumers, uses patented analytics and big data technology to turn billions of disparate online conversations into meaningful social intelligence.  With 2 billion posts analyzed and continuously expanding, Treato is partnered with 13 of the top 50 pharmaceutical companies and is its' consumer desktop and mobile sites see millions of visitors each month.

Treato is privately held with offices in Israel and Princeton, NJ. Investors include Reed Elsevier Ventures, OrbiMed Partners and New Leaf Venture Partners, among others. For more information please visit http://treato.com and http://corp.treato.com.

Supporting Resources: 

• Learn more on the Treato blog
• Like Treato on Facebook
• Follow Treato on LinkedIn
• Follow Treato on Twitter: @Treato_com

FOR IMMEDIATE RELEASE
Karen Kuller
Senior Director, Marketing
+972-54-286-6663
[email protected]

Alicia Libucha
Media Relations
+1-857-205-0919
[email protected]

SOURCE Treato

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED